Background: Cognitive fluctuations refer to alterations in cognition, attention, or arousal occurring over minutes to hours, most commonly in patients with dementias associated with advanced Lewy body pathology. Their pathophysiologic underpinning remains undetermined.
Case Presentation: We documented serial blood pressure (BP) measurements in an 86-year-old man with Parkinson's disease dementia experiencing cognitive fluctuations during an office visit. This patient's associated dysautonomia included labile BP with orthostatic hypotension and nocturnal hypertension. A spontaneous episode of unresponsiveness occurred while his BP was 72/48. His mental status began to recover immediately as his BP increased to 84/56 when he was placed in a recumbent position; it fully returned to baseline when it reached 124/66 within 1 min. His heart rate remained in the mid-to-high 60s throughout. Subsequent treatment with midodrine markedly reduced the frequency of cognitive fluctuations.
Conclusions: Paroxysmal hypotension may represent an explanatory mechanism for cognitive fluctuations, a common clinical feature in patients with Parkinson's disease dementia and dementia with Lewy bodies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5811960 | PMC |
| http://dx.doi.org/10.1186/s40734-018-0068-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Applying Natural Language Processing Techniques to Map Trends in Insomnia Treatment Terms on the r/Insomnia Subreddit: Infodemiology Study.
J Med Internet Res
January 2025
Division of Sleep Medicine, Harvard Medical School, Boston, MA, United States.
Background: People share health-related experiences and treatments, such as for insomnia, in digital communities. Natural language processing tools can be leveraged to understand the terms used in digital spaces to discuss insomnia and insomnia treatments.
Objective: The aim of this study is to summarize and chart trends of insomnia treatment terms on a digital insomnia message board.
Background: Characterizing pathological and functional features of the preclinical stage of Alzheimer's Disease (AD) is essential as Amyloid beta (Aβ) and tau, the pathological hallmarks of AD, start to accumulate years prior to the onset of clinical symptoms. Whether Aβ and/or tau are related to the brain's ability to functionally reconfigure in time (functional flexibility) remains unclear despite its important role in behavior and cognition.
Method: We included 233 cognitively unimpaired individuals with family history of AD from the PREVENT-AD cohort who underwent both Positron Emission Tomography (PET) and functional Magnetic Resonance Imaging (fMRI).
Biomarkers.
Alzheimers Dement
December 2024
Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA.
Background: Highly specific ATN plasma biomarker assays for neurodegenerative diseases have been developed, but their associations with cognition vary in different populations. Kidney disease, common in diabetes, may decrease the predictive precision of those biomarkers. The aim of this study was to characterize for the first time the relationships between plasma ATN biomarkers and cognitive function in adults with T1D.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Department for Neurology, UMC Ljubljana, Ljubljana, Slovenia.
Background: Dementia with Lewy bodies (DLB) is a an α-synucleinopathy characterized by dementia and a combination of parkinsonism, visual hallucinations, fluctuating cognition or REM sleep behaviour disorder. Specific biomarkers for DLB are lacking. DLB-related pattern (DLBRP) is a metabolic network imaging biomarker which expression can be quantified on a single patient basis.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA.
Background: Cognitive dysfunction is more common in individuals with type 1 diabetes (T1D) compared to the general population. Blood-based biomarkers are accurate in identifying early signs of neurodegeneration. However, studies using these biomarkers in T1D are lacking.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!